Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Tumor markers are ‘valuable’ for relapse detection in rare CNS tumors
Among evaluable patients, 92% of relapses were detectable by tumor markers.
News
Sequential chemoradiation improves DFS in early-stage cervical cancer
The 3-year disease-free survival rate was significantly higher among patients who received sequential chemoradiation than among patients who...
News
Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC
Adding tiragolumab to atezolizumab led to “clinically meaningful” improvements in patients with PD-L1–positive non–small cell lung cancer.
News
No OS benefit with gefitinib vs. chemo for EGFR+ NSCLC
Adjuvant gefitinib improved disease-free survival, but not overall survival, when compared with standard chemotherapy.
News
Addressing racism, bias in the American maternal mortality crisis
“I think the most important thing you can do is really consider a patient a partner in the care you give them.”
News
Poziotinib provides ‘modest but meaningful’ efficacy in NSCLC subgroup
About 15% of patients achieved a response with poziotinib and 65% had a decrease in tumor size.
News
ALTERNATE trial: No fulvestrant benefit in locally advanced ER+ HER2– breast cancer
The endocrine-sensitive disease rate was similar whether patients received anastrozole alone, fulvestrant alone, or fulvestrant plus anastrozole...
News
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBC
Ipatasertib provided a “clinically meaningful,” but not statistically significant, 9-month improvement in median overall survival.
News
Novel penclomedine shows promise for some AYAs with CNS cancers
Two patients who responded to the treatment were in their 59th month of survival at last follow-up.
News
Universal CAR-T therapy produces CRs in relapsed/refractory T-ALL
All five patients studied achieved a complete response, though one patient had a morphological relapse.
News
MRD surveillance can detect relapse before imaging in early-stage NSCLC
Relapse occurred in 9 of 10 patients who were positive for minimal residual disease but had no evidence of relapse on imaging.
News
The American maternal mortality crisis: The role of racism and bias
Not only do health care providers need to face their implicit biases, the health care system needs to change.
News
EMBRACA shows no overall survival benefit with talazoparib
Talazoparib did not confer an overall survival benefit over chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast...